

NovaBay Pharmaceuticals, Inc.  
Form SC 13D/A  
April 16, 2019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13D/A**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 1)\***

**NOVABAY PHARMACEUTICALS, INC.**

(Name of Issuer)

**Common Stock, \$0.01 par value**

(Title of Class of Securities)

**66987P201**

(CUSIP Number)

**OP Financial Investments Limited**

**Attn: Yanbin (Lawrence) Liu**

**27/F, Two Exchange Square**

**8 Connaught Place**

**Central, Hong Kong**

**TEL: +852-21350281**

(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

**March 21, 2019**

Edgar Filing: NovaBay Pharmaceuticals, Inc. - Form SC 13D/A

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13D-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

CUSIP No. 66987P201

SCHEDULE 13D

Name of  
Reporting  
Person

1.  
OP Financial  
Investments  
Limited

Check the  
appropriate  
box if a  
member of a  
group

2.
  - a.
  - b.

SEC Use  
Only

- 3.

4. Source of  
Funds

WC

5. Check if  
Disclosure of  
Legal  
Proceedings  
is Required  
Pursuant to  
Item 2(d) or  
2(e)

6. Citizenship  
or Place of  
Organization

Cayman  
Islands  
NUMBER OF

Sole Voting Power

SHARES

7.  
0

BENEFICIALLY

Shared Voting power

OWNED BY

8.  
0

EACH

REPORTING 9. Sole Dispositive Power

PERSON 0

WITH

10. Shared Dispositive Power

0

Aggregate  
Amount  
Beneficially  
Owned by  
Each  
Reporting  
11. Person

0

Check if the  
Aggregate  
Amount in  
Row (11)  
Excludes  
12. Certain  
Shares

Percent of  
Class  
Represented  
by Amount  
in Row (11)  
13.

0%

Type of  
Reporting  
Person

14.

IV, CO

---

**Item 1. Security and Issuer.**

This statement relates to the common stock, \$0.01 par value per share (the “**Shares**”), of NovaBay Pharmaceuticals, Inc. (the “**Company**”), a Delaware corporation.

Address of Issuer’s Principal Executive Offices:

2000 Powell Street, Suite 1150

Emeryville, California 94608

**Item 2. Identity and Background**

This statement is being filed by the following Reporting Person:

OP Financial Investments Limited (“**OP Financial**”)

Place of Organization:

OP Financial is a public company organized in the Cayman Islands.

Principal Business:

The principal business of OP Financial is as an investment firm focused on cross-border investment opportunities.

Address of Principal Business Office or, if none, Residence:

OP Financial Investments Limited

27/F, Two Exchange Square

8 Connaught Place

Central, Hong Kong

(d) During the last five years, the Reporting Person was not convicted of a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) During the last five years, the Reporting Person was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

---

**Item 3. Source and Amount of Funds or Other Consideration.**

This item is not applicable.

**Item 4. Purpose of Transaction.**

This item is not applicable.

**Item 5. Interest in Securities of the Issuer.**

(a) OP Financial is the beneficial owner of 0 Shares, which represents 0% of all outstanding Shares.

(b)

Sole Voting Power: 0

Shared Voting Power: 0

Sole Dispositive Power: 0

Shared Dispositive Power: 0

(c) Effective March 21, 2019, OP Financial entered into a Shares Sale and Purchase Agreement with Mr. Jian Ping Fu, pursuant to which it sold 1,700,000 Shares to Mr. Fu.

(d) This item is not applicable.

(e) March 21, 2019

**Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.**

The information provided in Item 5 is hereby incorporated by reference herein.

**Item 7. Material to Be Filed as Exhibits.**

This item is not applicable.

---

**Signature**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: April 16,  
2019

OP Financial  
Investments  
Limited

/s/ Gaobo Zhang  
Mr. Gaobo Zhang

Chief Executive  
Officer